Table 4 Difference in sPSA detection rate due to previous endocrine therapy (n = 58)
From: Clinical significance of serum PSA in breast cancer patients
| n | sPSA positive (%) | sPSA negative (%) | p value | |
|---|---|---|---|---|
| Aromatase inhibitor resistance | 0.1389 | |||
| Yes | 37 | 16 (43.2) | 21 (56.8) | |
| No | 21 | 5 (23.8) | 16 (76.2) | |
| SERM resistance | 0.4584 | |||
| Yes | 23 | 7 (30.4) | 16 (69.6) | |
| No | 35 | 14 (40.0) | 21 (60.0) | |
| SERD resistance | 0.2643 | |||
| Yes | 12 | 6 (50.0) | 6 (50.0) | |
| No | 46 | 15 (32.6) | 31 (67.4) | |
